What is Envveno Med Corp's earnings per share (EPS)?

Envveno Med Corp (NVNBW) reported diluted earnings per share of $-1.27 for fiscal year 2024. This represents a 33.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Envveno Med Corp Financials

NVNBW

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Envveno Med Corp (NVNBW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

1/9

Envveno Med Corp passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.77x

For every $1 of reported earnings, Envveno Med Corp generates $0.77 in operating cash flow (-$16.8M OCF vs -$21.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$23.6M

YoY+5.5%

Envveno Med Corp's EBITDA was -$23.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 5.5% from the prior year.

Net Income

-$21.8M

YoY+7.2%

Envveno Med Corp reported -$21.8M in net income in fiscal year 2024. This represents an increase of 7.2% from the prior year.

EPS (Diluted)

$-1.27

YoY+33.5%

Envveno Med Corp earned $-1.27 per diluted share (EPS) in fiscal year 2024. This represents an increase of 33.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$16.9M

YoY+10.7%

Envveno Med Corp generated -$16.9M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 10.7% from the prior year.

Cash & Debt

$1.8M

YoY-51.5%

5Y CAGR+6.1%

Envveno Med Corp held $1.8M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

18M

YoY+31.7%

Envveno Med Corp had 18M shares outstanding in fiscal year 2024. This represents an increase of 31.7% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-51.7%

YoY-0.8pp

5Y CAGR+718.5pp

Envveno Med Corp's ROE was -51.7% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 0.8 percentage points from the prior year.

Capital Allocation

R&D Spending

$12.2M

YoY-9.8%

5Y CAGR+40.9%

Envveno Med Corp invested $12.2M in research and development in fiscal year 2024. This represents a decrease of 9.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$37K

YoY+12.1%

5Y CAGR-36.7%

Envveno Med Corp invested $37K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 12.1% from the prior year.

NVNBW Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	N/A	N/A	N/A	$31K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$12.2M-9.8%	$13.6M+37.0%	$9.9M+73.1%	$5.7M+34.7%	$4.3M+92.7%	$2.2M
SG&A Expenses	$11.6M-0.7%	$11.7M-22.4%	$15.0M+34.5%	$11.2M+128.7%	$4.9M-0.6%	$4.9M
Operating Income	-$23.8M+5.6%	-$25.2M-1.2%	-$24.9M-47.6%	-$16.9M-84.9%	-$9.1M-19.0%	-$7.7M
Interest Expense	N/A	N/A	$161K+747.4%	$19K+408.2%	$4K+107.5%	-$50K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$21.8M+7.2%	-$23.5M+4.7%	-$24.7M-49.3%	-$16.5M-80.9%	-$9.1M-19.8%	-$7.6M
EPS (Diluted)	$-1.27+33.5%	$-1.91+13.2%	$-2.20	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$2.6M-10.6%	$2.9M+13.1%	$2.6M	N/A	$2.9M+1.2%	$2.8M-7.4%	$3.1M	N/A
SG&A Expenses	$2.3M-44.7%	$4.2M+73.5%	$2.4M	N/A	$3.3M+25.9%	$2.6M+7.3%	$2.5M	N/A
Operating Income	-$4.9M+30.7%	-$7.0M-42.3%	-$5.0M	N/A	-$6.2M-13.1%	-$5.5M+0.9%	-$5.5M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$4.5M+32.2%	-$6.7M-48.7%	-$4.5M	N/A	-$5.6M-13.8%	-$5.0M+0.7%	-$5.0M	N/A
EPS (Diluted)	$-0.23+30.3%	$-0.33-50.0%	$-0.22	N/A	$-0.35-12.9%	$-0.310.0%	$-0.31	N/A

NVNBW Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$45.0M-7.6%	$48.6M+16.7%	$41.7M-27.8%	$57.7M+447.5%	$10.5M+206.8%	$3.4M
Current Assets	$43.7M-6.8%	$46.9M+19.0%	$39.4M-28.4%	$55.0M+475.2%	$9.6M+572.0%	$1.4M
Cash & Equivalents	$1.8M-51.5%	$3.6M-20.5%	$4.6M-91.7%	$54.7M+486.3%	$9.3M+614.1%	$1.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.8M+14.8%	$2.4M-17.0%	$2.9M-11.0%	$3.3M-4.2%	$3.4M+40.7%	$2.4M
Current Liabilities	$2.1M+52.8%	$1.4M-10.4%	$1.5M-3.2%	$1.6M-50.4%	$3.2M+69.8%	$1.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$42.2M-8.7%	$46.2M+19.3%	$38.7M-28.8%	$54.4M+666.5%	$7.1M+617.0%	$990K
Retained Earnings	-$151.9M-16.8%	-$130.0M-22.1%	-$106.5M-30.1%	-$81.9M-25.3%	-$65.3M-16.3%	-$56.2M

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$32.4M-11.6%	$36.6M-9.9%	$40.6M-9.7%	$45.0M-10.8%	$50.4M+22.9%	$41.0M-8.6%	$44.8M-7.8%	$48.6M
Current Assets	$31.5M-11.5%	$35.6M-9.8%	$39.5M-9.7%	$43.7M-10.8%	$49.1M+24.1%	$39.5M-8.6%	$43.2M-7.8%	$46.9M
Cash & Equivalents	$1.5M-24.5%	$2.0M-30.4%	$2.9M+67.4%	$1.8M-90.2%	$17.9M+652.7%	$2.4M+2.9%	$2.3M-36.1%	$3.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.9M-17.5%	$3.5M+55.1%	$2.3M-18.8%	$2.8M-7.5%	$3.0M+17.2%	$2.6M+4.8%	$2.5M+1.0%	$2.4M
Current Liabilities	$2.4M-20.4%	$3.0M+81.5%	$1.7M-20.7%	$2.1M-6.0%	$2.2M+31.5%	$1.7M+14.0%	$1.5M+8.5%	$1.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$29.4M-10.9%	$33.1M-13.7%	$38.3M-9.1%	$42.2M-11.0%	$47.4M+23.3%	$38.4M-9.3%	$42.4M-8.3%	$46.2M
Retained Earnings	-$167.6M-2.8%	-$163.1M-4.3%	-$156.4M-3.0%	-$151.9M-4.3%	-$145.6M-4.0%	-$140.0M-3.7%	-$135.0M-3.8%	-$130.0M

NVNBW Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$16.8M+10.7%	-$18.9M-20.7%	-$15.6M-31.8%	-$11.8M-54.3%	-$7.7M-30.2%	-$5.9M
Capital Expenditures	$37K+12.1%	$33K-71.3%	$115K-68.8%	$368K+104.1%	$180K-50.5%	$364K
Free Cash Flow	-$16.9M+10.7%	-$18.9M-20.1%	-$15.7M-28.8%	-$12.2M-55.5%	-$7.9M-25.5%	-$6.3M
Investing Cash Flow	$1.3M+117.0%	-$7.9M+77.2%	-$34.6M-9289.7%	-$368K-104.1%	-$180K+50.5%	-$364K
Financing Cash Flow	$13.6M-47.1%	$25.8M	N/A	$57.6M+282.1%	$15.1M+167.4%	$5.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	-$4.4M-18.2%	-$3.7M+7.5%	-$4.0M+21.3%	-$5.1M-19.4%	-$4.3M-9.4%	-$3.9M-10.1%	-$3.5M+28.6%	-$5.0M
Capital Expenditures	$0	N/A	N/A	$4K-55.6%	$9K-35.7%	$14K+40.0%	$10K+150.0%	$4K
Free Cash Flow	-$4.4M	N/A	N/A	-$5.1M-19.2%	-$4.3M-9.3%	-$3.9M-10.1%	-$3.6M+28.5%	-$5.0M
Investing Cash Flow	$3.7M+29.4%	$2.8M-45.7%	$5.2M+147.0%	-$11.1M-277.7%	$6.2M+56.6%	$4.0M+80.8%	$2.2M+109.9%	-$22.1M
Financing Cash Flow	N/A	N/A	N/A	$0-100.0%	$13.6M	$0-100.0%	$46K	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

NVNBW Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	-24566.5%
Net Margin	N/A	N/A	N/A	N/A	N/A	-24406.7%
Return on Equity	-51.7%-0.8pp	-50.9%+12.8pp	-63.7%-33.3pp	-30.4%+98.3pp	-128.7%+641.6pp	-770.3%
Return on Assets	-48.5%-0.2pp	-48.4%+10.9pp	-59.2%-30.6pp	-28.6%+58.0pp	-86.7%+135.4pp	-222.0%
Current Ratio	20.88-13.4	34.23+8.5	25.78-9.1	34.84+31.8	3.00+2.2	0.76
Debt-to-Equity	0.07+0.0	0.05-0.0	0.08+0.0	0.06-0.4	0.48-2.0	2.47
FCF Margin	N/A	N/A	N/A	N/A	N/A	-20037.4%

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-15.4%+4.8pp	-20.3%-8.5pp	-11.8%	N/A	-11.9%+1.0pp	-12.9%-1.1pp	-11.8%	N/A
Return on Assets	-14.0%+4.3pp	-18.3%-7.2pp	-11.1%	N/A	-11.2%+0.9pp	-12.1%-0.9pp	-11.1%	N/A
Current Ratio	13.12+1.3	11.81-12.0	23.77+2.9	20.88-1.1	22.01-1.3	23.33-5.8	29.08-5.1	34.23
Debt-to-Equity	0.100.0	0.11+0.0	0.060.0	0.070.0	0.060.0	0.070.0	0.060.0	0.05
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Frequently Asked Questions

Is Envveno Med Corp profitable?

No, Envveno Med Corp (NVNBW) reported a net income of -$21.8M in fiscal year 2024.

What is Envveno Med Corp's EBITDA?

Envveno Med Corp (NVNBW) had EBITDA of -$23.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Envveno Med Corp's return on equity (ROE)?

Envveno Med Corp (NVNBW) has a return on equity of -51.7% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Envveno Med Corp's free cash flow?

Envveno Med Corp (NVNBW) generated -$16.9M in free cash flow during fiscal year 2024. This represents a 10.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Envveno Med Corp's operating cash flow?

Envveno Med Corp (NVNBW) generated -$16.8M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Envveno Med Corp's total assets?

Envveno Med Corp (NVNBW) had $45.0M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Envveno Med Corp's capital expenditures?

Envveno Med Corp (NVNBW) invested $37K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Envveno Med Corp spend on research and development?

Envveno Med Corp (NVNBW) invested $12.2M in research and development during fiscal year 2024.

How many shares does Envveno Med Corp have outstanding?

Envveno Med Corp (NVNBW) had 18M shares outstanding as of fiscal year 2024.

What is Envveno Med Corp's current ratio?

Envveno Med Corp (NVNBW) had a current ratio of 20.88 as of fiscal year 2024, which is generally considered healthy.

What is Envveno Med Corp's debt-to-equity ratio?

Envveno Med Corp (NVNBW) had a debt-to-equity ratio of 0.07 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Envveno Med Corp's return on assets (ROA)?

Envveno Med Corp (NVNBW) had a return on assets of -48.5% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Envveno Med Corp's cash runway?

Based on fiscal year 2024 data, Envveno Med Corp (NVNBW) had $1.8M in cash against an annual operating cash burn of $16.8M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Envveno Med Corp's Piotroski F-Score?

Envveno Med Corp (NVNBW) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Envveno Med Corp's earnings high quality?

Envveno Med Corp (NVNBW) has an earnings quality ratio of 0.77x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.